Omeros (NASDAQ:OMER) Shares Down 3.9% – Here’s What Happened

Omeros Co. (NASDAQ:OMER) traded down 3.9% on Monday . The stock traded as low as $10.34 and last traded at $10.48. 196,614 shares traded hands during trading, a decline of 60% from the average session volume of 491,331 shares. The stock had previously closed at $10.91.

Wall Street Analyst Weigh In

OMER has been the topic of several recent research reports. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a report on Thursday, November 14th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Thursday, November 14th. Finally, Rodman & Renshaw began coverage on Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price for the company. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $9.00.

Omeros Trading Down 2.0 %

The company has a market capitalization of $690.18 million, a PE ratio of -5.29 and a beta of 1.47. The stock’s 50-day moving average is $4.83 and its two-hundred day moving average is $4.36.

Institutional Investors Weigh In On Omeros

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its holdings in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the period. MML Investors Services LLC grew its holdings in Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 3,000 shares in the last quarter. SPC Financial Inc. bought a new stake in shares of Omeros in the 3rd quarter valued at about $77,000. SG Americas Securities LLC purchased a new stake in shares of Omeros in the 3rd quarter worth approximately $80,000. Finally, Comerica Bank increased its holdings in Omeros by 20.0% during the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 5,000 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.